drugset / Trial / NCT03314922

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

NCT03314922

Phase 1 Completed 17 enrolled Incyte Corporation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of parsaclisib in the treatment of Japanese participants diagnosed with previously-treated B-cell lymphoma.

Timeline

Start
2018-08-02
Primary completion
2020-05-05
Completion
2023-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Small molecule Oral

Indications